All News
Belimumab in Lupus Nephritis
Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.
Read Article
Orbitofrontal Cortex Implants to Assess Chronic Pain
Nature Neuroscience reports a novel approach to assessing chronic neuropathic pain - intracranial electrodes in the anterior cingulate cortex and orbitofrontal cortex (OFC) to map chronic pain signaling.
Read Article
Lupus Landmark Study to Accelerate Personalized Lupus Treatments
The Lupus Landmark Study, the largest study of its kind in lupus, will prospectively recruit and longitudinally follow 3,500 adults diagnosed with SLE.
https://t.co/nzCqk8AxK6 https://t.co/IS9OS08CmH
Links:
Dr. John Cush RheumNow ( View Tweet)
Tonight! The final Tuesday Night Rheumatology of May.
This webinar will feature highlights from these lectures followed by live audience Q & A:
Methotrexate Use: 50 Yr. Perspective
Myths vs Reality in RA
Biosimilars - Back on the Agenda
https://t.co/NRAtlQ96e3 https://t.co/j6WVyFacUc
Links:
Dr. John Cush RheumNow ( View Tweet)
TAS5315, BTK inhibitor, studied in 91 MTX refractory RA pts. Wk 12 ACR20 resp was 79% on TAS5315 vs 60% PBO (p=0.053); ACR50 (33 vs 13%) not signif. Adverse event equal betw grps, but 9 pts had bleeding on TAS5315 https://t.co/XYS0XRMJar https://t.co/ntGtahFf4T
Links:
Dr. John Cush RheumNow ( View Tweet)
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2
Links:
Dr. John Cush RheumNow ( View Tweet)
Systematic review proves Keystones 60%/40%/20% response rule in biologic-naive #RA. 21 RCTs 1999-2017; For bio-naïve pts the ACR20/50/70 was 61.4%/37.8%/ 18.8%. For Bio-IR it was 48.5%/27.3%/12.9%- roughly 10pts lower. https://t.co/Xr3QEw278J https://t.co/OAfNghXlvB
Links:
Dr. John Cush RheumNow ( View Tweet)
UK Biobank cohort study (n=361,952) assessed BMI effects on rheumatic Dz risk. Higher BMI incr odds of RA (IRR=1.52), OA (IRR=1.49), PsA (IRR=1.80), gout (1.73), SpA(1.34); more pronounced in women for both gout and psoriatic arthropathy https://t.co/eLeeShSSv1 https://t.co/IjWF2EPqOR
Links:
Dr. John Cush RheumNow ( View Tweet)
PREVENT study looked at Xray progression in 438 nr-axSpA pts given PBO or secukinumab. At baseline there was little SI damage & at 2 yrs no SI progression (− 0.04 mSASSS) or spinal inflammation in both groups. https://t.co/3EgnK2rWgb https://t.co/z5umUhpViF
Links:
Dr. John Cush RheumNow ( View Tweet)
MRI study of SI jts in axSpA 196 pts shows w/ increasing bone marrow edema of SI, SI damage is likely. BME each quadrant incr odds: sclerosis (OR:1.9), erosions (1.9). BME lead to 5 yr SIJ damage if fluctuating (OR:5.6) or persistent (OR:7.5) https://t.co/Dkbcij5Uhv https://t.co/x83kErVb1E
Links:
Dr. John Cush RheumNow ( View Tweet)
A claims cohort comparison of #RA pts with H.zoster (n 1 866 ) and pts without HZ (38,846). RA+/HZ+ pts had significantly greater Hospitalizations, emergency visits (esp <30d post HZ Dx; adj IRR hosp=3.4; ED=3.7) and higher Total HC costs https://t.co/89GLUK93dO https://t.co/9jweduoBHw
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for:
-KOL perspective videos
-Clinical Trial Highlights
-Daily Faculty Recaps
-Live Streaming
and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
Join us for the final Tuesday Night Rheumatology of May.
This webinar will feature highlights from these lectures followed by live audience Q & A:
Methotrexate Use: 50 Yr. Perspective
Myths vs Reality in RA
Biosimilars - Back on the Agenda
https://t.co/0OenWkXarV https://t.co/yUHwslkZ9o
Links:
Dr. John Cush RheumNow ( View Tweet)
3-4-5 Rule
Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on https://t.co/V10S4oVFsv
https://t.co/4iQERIh5Zl https://t.co/bwSk9L7ucC
Dr. John Cush RheumNow ( View Tweet)
⚠️Beware not all bone marrow oedema =#AxSpA on MRI !
Signal seen in 17% volunteers at SIJs
@DrPoddubnyy
#RNL2023 https://t.co/xTKuSRXK72 https://t.co/c09QjSkJBP
Links:
Dr. John Cush RheumNow ( View Tweet)
FRAX Tool is Suboptimal in Predicting Osteoporosis Fracture Risk in Younger Post-menopausal Women
https://t.co/8tc51AJ14n https://t.co/lhF7iwl0N3
Links:
Dr. John Cush RheumNow ( View Tweet)
With all the new adalimumab biosimilars happening in 2023, where's the pen? Now the FDA has approved an ADA biosimilar, Cyltezo, Autoinjector Pen! https://t.co/TgsA46xGsv https://t.co/rXcRcp7tDX
Links:
Dr. John Cush RheumNow ( View Tweet)
Dennis Poddubnyy #RNL2023
MRI sequences for axSpA:
Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression
Semi-axial- T2 STIR
@RheumNow https://t.co/aidLu7GcQH https://t.co/YOrboYl6pW
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: GPA Treatment Choices
https://t.co/9v6C5nOLqu https://t.co/1E347ulsvR
Links:
Dr. John Cush RheumNow ( View Tweet)
Colchicine does not work in Hand OA. Danish trial of 100 HOA pts (age 71 yrs) given placebo or COL 0.5 mg bid x 12wk. Finger pain improved –13·9 mm w/ colchicine vs –13·5 mm w/ PBO (NS). More adverse events w/ Colchicine (72% vs 44%) https://t.co/042BQcAFWf https://t.co/EldLmjVisD
Links:
Dr. John Cush RheumNow ( View Tweet)
